We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
-4.81%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$280M
AUM Growth
-$87.1M
Cap. Flow
-$47.5M
Cap. Flow %
-16.99%
Top 10 Hldgs %
59.73%
Holding
57
New
12
Increased
11
Reduced
3
Closed
20

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$19.9M
2
MRUS
Merus
MRUS
+$18.4M
3
NUVL
Nuvalent
NUVL
+$17.6M
4
SLNO
Soleno Therapeutics
SLNO
+$11.4M
5
RVMD icon
Revolution Medicines
RVMD
+$9.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$82M
2
NVO
Novo Nordisk
NVO
+$58.6M
3
VKTX icon
Viking Therapeutics
VKTX
+$25.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.79M
5
AXSM icon
Axsome Therapeutics
AXSM
+$7.89M

Sector Composition

Rank Sector Weight
1 Healthcare 88.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
$22.2M 7.94%
494,424
+220,000
+80% +$11.4M
MRUS
2
DELISTED
Merus
MRUS
$19.5M 6.97%
463,840
+383,669
+479% +$18.4M
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$18.4M 6.56%
219,719
+3,200
+1% +$263K
ACLX
4
DELISTED
Arcellx
ACLX
$17.6M 6.3%
+229,785
New +$19.9M
NVO
5
Novo Nordisk
NVO
$216B
$17.2M 6.15%
200,000
-541,743
-73% -$58.6M
NVO
6
PUT
Novo Nordisk
NVO
$216B
$17.2M 6.15%
+200,000
New +$21.6M
NUVL
7
DELISTED
Nuvalent
NUVL
$16M 5.71%
204,045
+188,608
+1,222% +$17.6M
PCVX icon
8
Vaxcyte
PCVX
$7.89B
$13.3M 4.75%
162,255
+86,000
+113% +$8.54M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$36.3B
$13.3M 4.74%
56,400
+21,400
+61% +$5.63M
AZN icon
10
AstraZeneca
AZN
$263B
$12.5M 4.47%
95,376
– –
RVMD icon
11
Revolution Medicines
RVMD
$40.2B
$12.4M 4.44%
284,190
+188,305
+196% +$9.5M
VRNA
12
DELISTED
Verona Pharma
VRNA
$11.9M 4.24%
255,318
+106,728
+72% +$4.01M
INSM icon
13
Insmed
INSM
$23.2B
$11.6M 4.14%
167,939
+115,000
+217% +$8.28M
PTGX icon
14
Protagonist Therapeutics
PTGX
$8.75B
$11.3M 4.05%
293,851
+169,411
+136% +$7.39M
XBI icon
15
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$9.01M 3.22%
+100,000
New +$9.69M
JANX icon
16
Janux Therapeutics
JANX
$935M
$8.73M 3.12%
+162,976
New +$8.62M
ARGX icon
17
argenx
ARGX
$57.4B
$6.96M 2.49%
11,311
-3,827
-25% -$2.24M
NBIX icon
18
Neurocrine Biosciences
NBIX
$17.7B
$6.14M 2.2%
45,000
– –
NVO
19
CALL
Novo Nordisk
NVO
$216B
$4.3M 1.54%
+50,000
New +$5.41M
VKTX icon
20
Viking Therapeutics
VKTX
$4.04B
$3.63M 1.3%
90,279
-442,600
-83% -$25.2M
RYTM icon
21
Rhythm Pharmaceuticals
RYTM
$7B
$2.8M 1%
+50,000
New +$2.76M
CRNX icon
22
Crinetics Pharmaceuticals
CRNX
$8.86B
$2.34M 0.84%
45,765
– –
ELVN icon
23
Enliven Therapeutics
ELVN
$3.78B
$2.32M 0.83%
+102,900
New +$2.67M
SWTX
24
DELISTED
SpringWorks Therapeutics
SWTX
$1.95M 0.7%
53,930
– –
VRDN icon
25
Viridian Therapeutics
VRDN
$2.13B
$1.92M 0.69%
+100,000
New +$2.17M
1
2 3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
HSG
Helen Stephens Group Fort Worth, Texas $501M AUM 16.23% 1-Year Est. Return

Artia Global Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Artia Global Partners held 57 positions worth $280M, down 24% from $367M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artia Global Partners withdrew a net $47.5M in Q4 2024, closing 20 positions and reducing 3 holdings. Its most notable exit was Eli Lilly, an estimated $82M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 96% a quarter earlier.

Against the trend, Artia Global Partners opened a new position in Arcellx worth $17.6M.

  • Artia Global Partners's largest Q4 2024 buy was Arcellx: 229,785 shares worth $17.6M.
  • Artia Global Partners added most to Merus in Q4 2024, an estimated $18.4M increase.
  • Artia Global Partners's biggest Q4 2024 reduction was Novo Nordisk, cutting an estimated $58.6M.
  • Artia Global Partners fully exited Eli Lilly in Q4 2024, selling an estimated $82M.
  • Artia Global Partners's ten largest holdings make up 60% of its $280M portfolio in Q4 2024.
  • Artia Global Partners opened 12 new positions and closed 20 in Q4 2024.
  • Artia Global Partners's portfolio value fell 24% quarter-over-quarter to $280M.

Based on Artia Global Partners's 13F filing for Q4 2024, filed 14 Feb 2025.